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INTRODUCTION
Eosinophilic fasciitis (EF), first described by Shulman in 1974, 
is a rare disorder of unknown etiology characterized by symmet-
ric and painful swelling with progressive induration and thick-
ening of the skin and soft tissues.1-3 In Korea, EF was first report-
ed in 1980.4 Inflammation of the fascia is not associated with 
exposure to toxic chemicals or with collagen vascular disease. 
Peripheral eosinophilia is frequently present,5,6 and a good re-
sponse to systemic corticosteroid therapy is characteristic of EF. 
In this case, we describe a 19-year-old female with EF whose 
only initial symptom was symmetric pitting edema in her lower 
legs without skin abnormalities.
 
CASE REPORT
A 19-year-old female visited our hospital with a 2 week history 
of progressive pitting edema in both lower legs associated with 
a 2 kg weight gain. Symptom onset began shortly after intense 
physical exertion (dance practice). Her medical history includ-
ed allergic rhinitis with sensitization to house dust mite and 
pollen, and she had visited the pediatric allergy clinic for about 
10 years. None of her family members had a history of similar 
symptoms or specific diseases. Additionally, she noted mild 
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pain in both knees and ankles, but tenderness was not remark-
able on physical examination. She denied fever, dyspnea, chest 
pain, and urinary difficulty. She was not taking any medica-
tions. Physical examination revealed moderate bilateral pretib-
ial pitting edema. No redness, induration, or thickened skin was 
observed. No contractures of joints were found, and muscle 
strength was normal in the upper and lower extremities.
At first, she visited the cardiovascular surgery clinic and was 
admitted for evaluation and treatment of deep vein thrombo-
sis. However, computed tomography (CT) angiography of her 
lower extremities revealed no evidence of venous disturbance. 
Treatment with heparin and application of compression stock-
ings did not alleviate her symptoms. Initial laboratory findings 
included a white blood cell count of 8,090 cells/μL with 28.9% 
eosinophils. Her eosinophil count was 2,340 cells/μL. Her he-
moglobin level and platelet count were normal and her serum 
total IgE level was 786 kIU/L, but no remarkable change was 
Eosinophilic fasciitis is a rare disease characterized by diffuse fasciitis with peripheral eosinophilia and progressive induration and thickening of the 
skin and soft tissues. We report a 19-year-old female who presented with pitting edema in both lower extremities. She had a history of excessive 
physical activity before her symptoms developed. Physical examination revealed 2+ pitting edema in both lower legs. She complained of mild pain 
in both knee joints and feet, with no tenderness or heating sensations. Laboratory results were unremarkable except for severe eosinophilia. Para-
site infection, venous thrombosis, and cardiac and renal problems were excluded. A magnetic resonance imaging study of both lower extremities re-
vealed increased signal intensity in the subcutaneous lesions, consistent with superficial inflammation of the fascia. Mixed perivenular lymphoplas-
macytic and eosinophilic infiltration in the subcutaneous lesion were observed on biopsy. The patient was treated with corticosteroids, resulting in 
remarkable improvement in both edema and eosinophilia.
Key Words: Eosinophilia; eosinophilic fasciitis; pitting edema
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correspondence to: Kyu-Earn Kim, MD, PhD, Department of Pediatrics and 
Institute of Allergy, Gangnam Severance Hospital, Yonsei University College of 
Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea.
Tel: +82-2-2019-3353; Fax: +82-2-3461-9473; E-mail: kekim@yuhs.ac
Received: Feburary 27, 2013; Accepted: April 4, 2013
•There are no financial or other issues that might lead to conflict of interest.
Case Report
Allergy Asthma Immunol Res. 2014 March;6(2):179-182.
http://dx.doi.org/10.4168/aair.2014.6.2.179
pISSN 2092-7355 • eISSN 2092-7363
Lee et al.
Allergy Asthma Immunol Res. 2014 March;6(2):179-182. http://dx.doi.org/10.4168/aair.2014.6.2.179
Volume 6, Number 2, March 2014
180 http://e-aair.org
Fig. 1. Fat-saturated T2-weighted magnetic resonance imaging of the lower 
thigh of a patient with eosinophilic fasciitis. Arrows indicate inflammatory chang-
es in the superficial fascia and subcutaneous fat layer.
Fig. 2. Perivascular eosinophilic infiltration in deep dermal and subcutaneous 
fat tissue (×400).
observed compared to the previous year. The erythrocyte sedi-
mentation rate and C-reactive protein level were not elevated. 
Serum urea nitrogen and creatinine were normal and urinaly-
sis revealed no proteinuria or hematuria. Serum albumin was 
unremarkable at 4.2 g/dL. Serum protein electrophoresis results 
were within the normal range. Other laboratory data, including 
serum aminotransferase, alkaline phosphatase, cholesterol, 
and electrolyte levels, were normal. Further evaluations to de-
termine the cause of her symptoms and peripheral eosinophil-
ia were performed. There was no evidence of parasitic infection. 
A thyroid function test revealed normal thyroid function. The 
results of electrocardiogram and pulmonary function tests were 
normal. The patient was negative for rheumatoid factor and an-
tinuclear antibody. An abdominal ultrasound showed no path-
ological changes. However, during the time of evaluation, the 
patient’s blood eosinophil count increased rapidly to 4,880 cells/
μL.
The patient was referred to our division of pediatric allergy 
considering the findings of peripheral eosinophilia and a past 
history of allergy, and a magnetic resonance imaging (MRI) was 
performed in her lower thigh. As shown in Fig. 1, the signal in-
tensity of subcutaneous lesions was increased in fat-saturated 
T2-weighted images, suggesting inflammation of the subcuta-
neous fat layer and superficial fascia. Mild synovitis of both knees 
was also suggested. No evidence of thickening or fibrosis of the 
deep fascia was present. A biopsy of the right dorsal foot was 
performed, and the biopsy specimen included skin and under-
lying subcutaneous tissue. Biopsy examination revealed dermal 
edema and perivenular lymphoplasmacytic and eosinophilic 
infiltration in the subcutaneous fat tissue (Fig. 2). Based on the 
MRI and biopsy results, we diagnosed EF. We started intrave-
nous corticosteroid therapy: dexamethasone 15 mg/day on the 
day of diagnosis. After 2 days of dexamethasone therapy, the 
symmetric pitting edema improved dramatically. The eosino-
phil count decreased rapidly from 4,880 to 140 cells/μL. We 
changed the intravenous dexamethasone to 30 mg/day of oral 
prednisolone, and the patient received an additional day of 
therapy with oral steroids. After a total of 3 days of intravenous 
plus oral steroid therapy, the patient recovered fully. She was 
discharged from the hospital without medication. Mild edema-
tous changes in both legs developed 2 weeks later, but the pa-
tient’s symptoms immediately relieved after administration of 
30 mg/day prednisolone for 1day. She was monitored in an 
outpatient clinic for 4 months after cessation of therapy. The 
most recent eosinophil count was 320 cells/μL, and no relapses 
were observed.
DISCUSSION
When a young female presents with edema in both lower legs, 
common causes such as renal, cardiac, or venous problems 
should be considered. Here, we present a rare cause of symmet-
ric pitting edema in the lower extremities. Two prior case reports 
have suggested EF as an unusual cause of generalized edema7 
and pitting edema of the extremities.8 Common symptoms of 
EF include progressive thickening, redness, and hardness of the 
skin. The ‘groove sign’ of depressed veins suggests deep fascia 
involvement, which may be present in up to half of the patients 
with EF.9 The upper extremities are most often involved5,9; how-
ever, our patient showed no cutaneous manifestations except 
for pitting edema, and her upper extremities were not involved. 
It was uncommon that our patient was a 19-year-old female, 
because EF occurs predominantly in young males, and only 
rarely in women and children.10,11 A recent history of intense 
physical activity or trauma has been reported in 30%-46% of pa-
tients.5,6,9 Considerable physical movement in our patient dur-
ing dance practice may have acted as a disease trigger.
Although EF is characterized by unusual laboratory abnor-
malities such as peripheral blood eosinophilia, hypergamma-
globulinemia and an elevated erythrocyte sedimentation rate, 
these laboratory findings do not always correlate with disease 
activity or prognosis.1,5 In the present case, almost all of the lab-
oratory findings, including the serum protein electrophoresis 
results, were unremarkable. The only abnormal laboratory find-
ing was severe blood eosinophilia. In addition, the blood eosin-
ophil count increased rapidly during evaluation. There are no 
international diagnostic criteria for EF, although MRI and biop-
sy are accepted as diagnostic tools. Currently, full-thickness 
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skin in a muscle biopsy is the gold standard for diagnosing EF, 
and a biopsy will typically reveal thickened fascia and inflam-
matory infiltrates composed of lymphocytes and eosinophils.3,5,9 
Perivascular infiltrates of lymphocytes are almost always pres-
ent, while eosinophil infiltrates are present in 69%-75% of cas-
es.6,9 Several studies comparing MRI and biopsy results have 
demonstrated that MRI is useful for diagnosis of EF.12,13 Two cas-
es in which MRI generated equal or superior results compared 
to those obtained with biopsy have been reported.13 Further-
more, MRI can be helpful in determining the response to thera-
py.12 In our case, MRI revealed inflammation of the superficial 
fascia without definite fibrotic changes. Neither the clinical 
manifestations of our patient nor the MRI findings revealed ev-
idence of deep fascia or muscular involvement. The biopsy sam-
ple did not include deep fascia and muscle; however, consider-
ation of the MRI results and biopsy findings of cellular infiltra-
tion of lymphocytes and eosinophils in subcutaneous lesions 
together was sufficient for the diagnosis of EF.
The clinical manifestations of EF can mimic other diseases, 
and the diagnosis of EF might be delayed in patients presenting 
with muscular pain because EF exhibits similarities to myopa-
thies and eosinophilia-myalgia syndrome.14 Polyneuropathy or 
pulmonary disease or a history of L-tryptophan intake can dis-
tinguish eosinophilia-myalgia syndrome from EF. First, EF should 
be suspected when clinical symptoms and signs start to appear. 
For differential diagnoses, systemic sclerosis, scleroderma and 
mixed connective tissue disorders must also be considered.9 
Hematologic disorders might be associated with EF, including 
thrombocytopenia, aplastic anemia and various lymphomas.3,15,16
Treatment of EF usually consists of systemic corticosteroids.9 
In patients who do not respond to corticosteroids, immuno-
suppressive agents such as methotrexate, cyclosporin, hydroxy-
chloroquine, and photochemotherapies have been used.9,17,18 
In our case, a trial of short-term systemic corticosteroids was 
completely effective. The blood eosinophil count decreased 
dramatically, coinciding with an improvement in her symptoms; 
the change in the degree of eosinophilia was correlated with 
changes in symptoms. EF is usually benign, and 70%-90% of 
patients have been reported to experience a partial-to-complete 
response to corticosteroid therapy.5,9 Visceral involvement is 
extremely uncommon.9 Previous studies of pediatric patients 
with EF have suggested that a young age at the time of onset may 
be one of the prognostic factors for refractory fibrosis.6,11 It ap-
pears that EF with extensive skin involvement tends to advance 
to become a more severe disorder.11 
In summary, although EF is an unusual disorder, it should be 
considered when a patient presents with eosinophilia and sym-
metric edema of the extremities. Normal laboratory findings 
cannot exclude a diagnosis of EF. The majority of patients are 
steroid responsive, and a proper diagnosis and therapeutic ap-
proach are critical for preventing long-term morbidity.
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